下载PDF
{"title":"作者对 \"食品药品管理局不良事件报告系统中与胰高血糖素样肽-1 受体激动剂相关的甲状腺增生和肿瘤不良事件 \"同行评审的回应:回顾性分析\"。","authors":"Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan","doi":"10.2196/58273","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73558,"journal":{"name":"JMIRx med","volume":"5 ","pages":"e58273"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090022/pdf/","citationCount":"0","resultStr":"{\"title\":\"Authors' Response to Peer Reviews of \\\"Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis\\\".\",\"authors\":\"Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan\",\"doi\":\"10.2196/58273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73558,\"journal\":{\"name\":\"JMIRx med\",\"volume\":\"5 \",\"pages\":\"e58273\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090022/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JMIRx med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2196/58273\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIRx med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/58273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
引用
批量引用